{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:27:27Z","timestamp":1790706447692,"version":"4.1.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T00:00:00Z","timestamp":1534118400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41386-018-0177-7","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T13:53:26Z","timestamp":1534168406000},"page":"683-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress"],"prefix":"10.1038","volume":"44","author":[{"given":"Xiaolei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Nedelcovych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit G.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisa","family":"Moreno-Megui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Coomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varun","family":"Vohra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Alt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Prchalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk\u00e1\u0161","family":"Tenora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Majer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Rais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4695-3048","authenticated-orcid":false,"given":"Camilo","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Slusher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,13]]},"reference":[{"key":"177_CR1","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","volume":"289","author":"RC Kessler","year":"2003","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095\u2013105.","journal-title":"JAMA"},{"key":"177_CR2","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1038\/sj.npp.1301652","volume":"33","author":"SJ Mathew","year":"2008","unstructured":"Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008;33:2080\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"177_CR3","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1038\/nn.4160","volume":"18","author":"K Sharma","year":"2015","unstructured":"Sharma K, Schmitt S, Bergner CG, Tyanova S, Kannaiyan N, Manrique-Hoyos N, et al. Cell type- and brain region-resolved mouse brain proteome. Nat Neurosci. 2015;18:1819\u201331.","journal-title":"Nat Neurosci"},{"key":"177_CR4","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","volume":"73","author":"JH Krystal","year":"2013","unstructured":"Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013;73:1133\u201341.","journal-title":"Biol Psychiatry"},{"key":"177_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrd.2017.16","volume":"16","author":"JW Murrough","year":"2017","unstructured":"Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017;16:472\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"177_CR6","unstructured":"Reus GZ, de Moura AB, Silva RH, Resende WR, Quevedo J (2017). Resilience dysregulation in major depressive disorder: focus on glutamatergic imbalance and microglial activation. Curr Neuropharmacol. 2018;16:297-307."},{"key":"177_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.8","volume":"6","author":"K Hashimoto","year":"2016","unstructured":"Hashimoto K, Bruno D, Nierenberg J, Marmar CR, Zetterberg H, Blennow K, et al. Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study. Transl Psychiatry. 2016;6:e744.","journal-title":"Transl Psychiatry"},{"key":"177_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF00345492","volume":"232","author":"JS Kim","year":"1982","unstructured":"Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr. 1982;232:299\u2013304.","journal-title":"Arch Psychiatr Nervenkr"},{"key":"177_CR9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S0006-3223(99)00284-X","volume":"47","author":"J Levine","year":"2000","unstructured":"Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry. 2000;47:586\u201393.","journal-title":"Biol Psychiatry"},{"key":"177_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05121-6","volume":"7","author":"H Umehara","year":"2017","unstructured":"Umehara H, Numata S, Watanabe SY, Hatakeyama Y, Kinoshita M, Tomioka Y, et al. Altered KYN\/TRP, Gln\/Glu, and Met\/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder. Sci Rep. 2017;7:4855.","journal-title":"Sci Rep"},{"key":"177_CR11","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/mp.2015.206","volume":"21","author":"E Haroon","year":"2016","unstructured":"Haroon E, Fleischer CC, Felger JC, Chen X, Woolwine BJ, Patel T, et al. Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry. 2016;21:1351\u20137.","journal-title":"Mol Psychiatry"},{"key":"177_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/mp.2015.83","volume":"21","author":"MS Milak","year":"2016","unstructured":"Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, et al. A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder. Mol Psychiatry. 2016;21:320\u20137.","journal-title":"Mol Psychiatry"},{"key":"177_CR13","doi-asserted-by":"publisher","first-page":"15028","DOI":"10.1038\/npjschz.2015.28","volume":"1","author":"R Taylor","year":"2015","unstructured":"Taylor R, Neufeld RW, Schaefer B, Densmore M, Rajakumar N, Osuch EA, et al. Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task. NPJ Schizophr. 2015;1:15028.","journal-title":"NPJ Schizophr"},{"key":"177_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.schres.2005.06.012","volume":"78","author":"LV Kristiansen","year":"2005","unstructured":"Kristiansen LV, Meador-Woodruff JH. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. Schizophr Res. 2005;78:87\u201393.","journal-title":"Schizophr Res"},{"key":"177_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2174\/1570159X14666160321123221","volume":"15","author":"BA Jaso","year":"2017","unstructured":"Jaso BA, Niciu MJ, Iadarola ND, Lally N, Richards EM, Park M, et al. Therapeutic modulation of glutamate receptors in major depressive disorder. Curr Neuropharmacol. 2017;15:57\u201370.","journal-title":"Curr Neuropharmacol"},{"key":"177_CR16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.biopsych.2016.05.005","volume":"81","author":"MS Lener","year":"2017","unstructured":"Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to ketamine. Biol Psychiatry. 2017;81:886\u201397.","journal-title":"Biol Psychiatry"},{"key":"177_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1001\/jamapsychiatry.2016.0838","volume":"73","author":"JA Quiroz","year":"2016","unstructured":"Quiroz JA, Tamburri P, Deptula D, Banken L, Beyer U, Rabbia M, et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. JAMA Psychiatry. 2016;73:675\u201384.","journal-title":"JAMA Psychiatry"},{"key":"177_CR18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nrd2462","volume":"7","author":"G Sanacora","year":"2008","unstructured":"Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7:426\u201337.","journal-title":"Nat Rev Drug Discov"},{"key":"177_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr.","year":"2006","unstructured":"Zarate CA,Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch General Psychiatry. 2006;63:856\u201364.","journal-title":"Arch General Psychiatry"},{"key":"177_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri.2015.5","volume":"16","author":"AH Miller","year":"2016","unstructured":"Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22\u201334.","journal-title":"Nat Rev Immunol"},{"key":"177_CR21","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.biopsych.2013.03.032","volume":"73","author":"G Sanacora","year":"2013","unstructured":"Sanacora G, Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry. 2013;73:1172\u20139.","journal-title":"Biol Psychiatry"},{"key":"177_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/npp.2016.199","volume":"42","author":"E Haroon","year":"2017","unstructured":"Haroon E, Miller AH, Sanacora G. Inflammation, glutamate, and glia: a trio of trouble in mood disorders. Neuropsychopharmacology. 2017;42:193\u2013215.","journal-title":"Neuropsychopharmacology"},{"key":"177_CR23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/71555","volume":"6","author":"D Pitt","year":"2000","unstructured":"Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med. 2000;6:67\u201370.","journal-title":"Nat Med"},{"key":"177_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/ana.1077","volume":"50","author":"P Werner","year":"2001","unstructured":"Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol. 2001;50:169\u201380.","journal-title":"Ann Neurol"},{"key":"177_CR25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.biopsych.2008.11.029","volume":"65","author":"AH Miller","year":"2009","unstructured":"Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732\u201341.","journal-title":"Biol Psychiatry"},{"key":"177_CR26","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1523\/JNEUROSCI.5966-09.2010","volume":"30","author":"I Maezawa","year":"2010","unstructured":"Maezawa I, Jin LW. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J Neurosci. 2010;30:5346\u201356.","journal-title":"J Neurosci"},{"key":"177_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bbrc.2013.11.043","volume":"443","author":"AG Thomas","year":"2014","unstructured":"Thomas AG, O\u2019Driscoll CM, Bressler J, Kaufmann W, Rojas CJ, Slusher BS. Small molecule glutaminase inhibitors block glutamate release from stimulated microglia. Biochem Biophys Res Commun. 2014;443:32\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"177_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s11481-013-9442-z","volume":"8","author":"MC Potter","year":"2013","unstructured":"Potter MC, Figuera-Losada M, Rojas C, Slusher BS. Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J NeuroImmune Pharmacol. 2013;8:594\u2013607.","journal-title":"J NeuroImmune Pharmacol"},{"key":"177_CR29","doi-asserted-by":"publisher","first-page":"21362","DOI":"10.1074\/jbc.M600504200","volume":"281","author":"H Takeuchi","year":"2006","unstructured":"Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, et al. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J Biol Chem. 2006;281:21362\u20138.","journal-title":"J Biol Chem"},{"key":"177_CR30","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.neuint.2005.11.017","volume":"48","author":"AR Jayakumar","year":"2006","unstructured":"Jayakumar AR, Rao KV, Murthy Ch R, Norenberg MD. Glutamine in the mechanism of ammonia-induced astrocyte swelling. Neurochem Int. 2006;48:623\u20138.","journal-title":"Neurochem Int"},{"key":"177_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1515\/revneuro-2012-0062","volume":"24","author":"M Kostic","year":"2013","unstructured":"Kostic M, Zivkovic N, Stojanovic I. Multiple sclerosis and glutamate excitotoxicity. Rev Neurosci. 2013;24:71\u201388.","journal-title":"Rev Neurosci"},{"key":"177_CR32","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1038\/npp.2009.58","volume":"34","author":"I Gaisler-Salomon","year":"2009","unstructured":"Gaisler-Salomon I, Miller GM, Chuhma N, Lee S, Zhang H, Ghoddoussi F, et al. Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia. Neuropsychopharmacol. 2009;34:2305\u201322.","journal-title":"Neuropsychopharmacol"},{"key":"177_CR33","doi-asserted-by":"publisher","first-page":"15195","DOI":"10.1523\/JNEUROSCI.2051-11.2011","volume":"31","author":"Y Huang","year":"2011","unstructured":"Huang Y, Zhao L, Jia B, Wu L, Li Y, Curthoys N, et al. Glutaminase dysregulation in HIV-1-infected human microglia mediates neurotoxicity: relevant to HIV-1-associated neurocognitive disorders. J Neurosci. 2011;31:15195\u2013204.","journal-title":"J Neurosci"},{"key":"177_CR34","doi-asserted-by":"publisher","first-page":"8981","DOI":"10.1158\/0008-5472.CAN-10-1666","volume":"70","author":"MJ Seltzer","year":"2010","unstructured":"Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010;70:8981\u20137.","journal-title":"Cancer Res"},{"key":"177_CR35","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1516544112","volume":"112","author":"EB Gordon","year":"2015","unstructured":"Gordon EB, Hart GT, Tran TM, Waisberg M, Akkaya M, Kim AS, et al. Targeting glutamine metabolism rescues mice from late-stage cerebral malaria. Proc Natl Acad Sci USA. 2015;112:13075\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"177_CR36","doi-asserted-by":"publisher","first-page":"9251","DOI":"10.1128\/JVI.01045-16","volume":"90","author":"S Manivannan","year":"2016","unstructured":"Manivannan S, Baxter VK, Schultz KL, Slusher BS, Griffin DE. Protective effects of glutamine antagonist 6-diazo-5-oxo-l-norleucine in mice with alphavirus encephalomyelitis. J Virol. 2016;90:9251\u201362.","journal-title":"J Virol"},{"key":"177_CR37","doi-asserted-by":"publisher","first-page":"7186","DOI":"10.1021\/acs.jmedchem.7b00966","volume":"60","author":"MT Nedelcovych","year":"2017","unstructured":"Nedelcovych MT, Tenora L, Kim BH, Kelschenbach J, Chao W, Hadas E, et al. N-(Pivaloyloxy)alkoxy-carbonyl prodrugs of the glutamine antagonist 6-diazo-5-oxo-l-norleucine (DON) as a potential treatment for HIV associated neurocognitive disorders. J Med Chem. 2017;60:7186\u201398.","journal-title":"J Med Chem"},{"key":"177_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s13365-015-0314-6","volume":"21","author":"MC Potter","year":"2015","unstructured":"Potter MC, Baxter VK, Mathey RW, Alt J, Rojas C, Griffin DE, et al. Neurological sequelae induced by alphavirus infection of the CNS are attenuated by treatment with the glutamine antagonist 6-diazo-5-oxo-l-norleucine. J Neurovirol. 2015;21:159\u201373.","journal-title":"J Neurovirol"},{"key":"177_CR39","doi-asserted-by":"publisher","first-page":"8621","DOI":"10.1021\/acs.jmedchem.6b01069","volume":"59","author":"R Rais","year":"2016","unstructured":"Rais R, Jancarik A, Tenora L, Nedelcovych M, Alt J, Englert J, et al. Discovery of 6-diazo-5-oxo-l-norleucine (DON) prodrugs with enhanced CSF delivery in monkeys: a potential treatment for glioblastoma. J Med Chem. 2016;59:8621\u201333.","journal-title":"J Med Chem"},{"key":"177_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1620\/tjem.217.87","volume":"217","author":"J Shijie","year":"2009","unstructured":"Shijie J, Takeuchi H, Yawata I, Harada Y, Sonobe Y, Doi Y, et al. Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice. Tohoku J Exp Med. 2009;217:87\u201392.","journal-title":"Tohoku J Exp Med"},{"key":"177_CR41","unstructured":"Francis TC, Chandra R, Gaynor A, Konkalmatt P, Metzbower SR, Evans B, et al. (2017). Molecular basis of dendritic atrophy and activity in stress susceptibility. Mol Psychiatry. 2017;22:1512-19."},{"key":"177_CR42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.cell.2007.09.018","volume":"131","author":"V Krishnan","year":"2007","unstructured":"Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell. 2007;131:391\u2013404.","journal-title":"Cell"},{"key":"177_CR43","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/mp.2017.64","volume":"23","author":"DB McKim","year":"2018","unstructured":"McKim DB, Weber MD, Niraula A, Sawicki CM, Liu X, Jarrett BL, et al. Microglial recruitment of IL-1beta-producing monocytes to brain endothelium causes stress-induced anxiety. Mol Psychiatry. 2018;23:1421\u201331.","journal-title":"Mol Psychiatry"},{"key":"177_CR44","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1126\/science.1120972","volume":"311","author":"O Berton","year":"2006","unstructured":"Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 2006;311:864\u20138.","journal-title":"Science"},{"key":"177_CR45","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/nn.2647","volume":"13","author":"EJ Nestler","year":"2010","unstructured":"Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nat Neurosci. 2010;13:1161\u20139.","journal-title":"Nat Neurosci"},{"key":"177_CR46","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.1523\/JNEUROSCI.0450-11.2011","volume":"31","author":"ES Wohleb","year":"2011","unstructured":"Wohleb ES, Hanke ML, Corona AW, Powell ND, Stiner LM, Bailey MT, et al. beta-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J Neurosci. 2011;31:6277\u201388.","journal-title":"J Neurosci"},{"key":"177_CR47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","volume":"83","author":"C Yang","year":"2018","unstructured":"Yang C, Ren Q, Qu Y, Zhang JC, Ma M, Dong C, et al. Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry. 2018;83:18\u201328.","journal-title":"Biol Psychiatry"},{"key":"177_CR48","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/nprot.2011.361","volume":"6","author":"SA Golden","year":"2011","unstructured":"Golden SA, Covington HE 3rd, Berton O, Russo SJ. A standardized protocol for repeated social defeat stress in mice. Nat Protoc. 2011;6:1183\u201391.","journal-title":"Nat Protoc"},{"key":"177_CR49","doi-asserted-by":"publisher","first-page":"6406","DOI":"10.1073\/pnas.0609625104","volume":"104","author":"K Roybal","year":"2007","unstructured":"Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V, et al. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci USA. 2007;104:6406\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"key":"177_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0876-8","volume":"14","author":"N Ito","year":"2017","unstructured":"Ito N, Hirose E, Ishida T, Hori A, Nagai T, Kobayashi Y, et al. Kososan, a Kampo medicine, prevents a social avoidance behavior and attenuates neuroinflammation in socially defeated mice. J Neuroinflamm. 2017;14:98.","journal-title":"J Neuroinflamm"},{"key":"177_CR51","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.bbi.2006.11.001","volume":"21","author":"SG Kinsey","year":"2007","unstructured":"Kinsey SG, Bailey MT, Sheridan JF, Padgett DA, Avitsur R. Repeated social defeat causes increased anxiety-like behavior and alters splenocyte function in C57BL\/6 and CD-1 mice. Brain Behav Immun. 2007;21:458\u201366.","journal-title":"Brain Behav Immun"},{"key":"177_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.biopsych.2013.12.009","volume":"76","author":"A Veerakumar","year":"2014","unstructured":"Veerakumar A, Challis C, Gupta P, Da J, Upadhyay A, Beck SG, et al. Antidepressant-like effects of cortical deep brain stimulation coincide with pro-neuroplastic adaptations of serotonin systems. Biol Psychiatry. 2014;76:203\u201312.","journal-title":"Biol Psychiatry"},{"key":"177_CR53","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/ijnp\/pyx079","volume":"21","author":"CA Browne","year":"2018","unstructured":"Browne CA, Falcon E, Robinson SA, Berton O, Lucki I. Reversal of stress-induced social interaction deficits by buprenorphine. Int J Neuropsychopharmacol. 2018;21:164\u201374.","journal-title":"Int J Neuropsychopharmacol"},{"key":"177_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nn1659","volume":"9","author":"NM Tsankova","year":"2006","unstructured":"Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006;9:519\u201325.","journal-title":"Nat Neurosci"},{"key":"177_CR55","unstructured":"Kaidanovich-Beilin O, Lipina T, Vukobradovic I, Roder J, Woodgett JR (2011). Assessment of social interaction behaviors. JoVE. 2011;48:e2473."},{"key":"177_CR56","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1601-183X.2004.00071.x","volume":"3","author":"JJ Nadler","year":"2004","unstructured":"Nadler JJ, Moy SS, Dold G, Trang D, Simmons N, Perez A, et al. Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav. 2004;3:303\u201314.","journal-title":"Genes Brain Behav"},{"key":"177_CR57","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nn.3641","volume":"17","author":"Y Zhan","year":"2014","unstructured":"Zhan Y, Paolicelli RC, Sforazzini F, Weinhard L, Bolasco G, Pagani F, et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci. 2014;17:400\u20136.","journal-title":"Nat Neurosci"},{"key":"177_CR58","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/nm.3162","volume":"19","author":"X Cao","year":"2013","unstructured":"Cao X, Li LP, Wang Q, Wu Q, Hu HH, Zhang M, et al. Astrocyte-derived ATP modulates depressive-like behaviors. Nat Med. 2013;19:773\u20137.","journal-title":"Nat Med"},{"key":"177_CR59","volume-title":"Paxinos and Franklin\u2019s the mouse brain in stereotaxic coordinates","author":"G Paxinos","year":"2013","unstructured":"Paxinos G, Franklin KBJ. Paxinos and Franklin\u2019s the mouse brain in stereotaxic coordinates. 4th edn. Amsterdam: Elsevier\/Academic Press; 2013.","edition":"4th edn"},{"key":"177_CR60","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.virol.2017.05.013","volume":"508","author":"VK Baxter","year":"2017","unstructured":"Baxter VK, Glowinski R, Braxton AM, Potter MC, Slusher BS, Griffin DE. Glutamine antagonist-mediated immune suppression decreases pathology but delays virus clearance in mice during nonfatal alphavirus encephalomyelitis. Virology. 2017;508:134\u201349.","journal-title":"Virology"},{"key":"177_CR61","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.biopsych.2015.08.009","volume":"79","author":"C Anacker","year":"2016","unstructured":"Anacker C, Scholz J, O\u2019Donnell KJ, Allemang-Grand R, Diorio J, Bagot RC, et al. Neuroanatomic differences associated with stress susceptibility and resilience. Biol Psychiatry. 2016;79:840\u20139.","journal-title":"Biol Psychiatry"},{"key":"177_CR62","doi-asserted-by":"publisher","first-page":"16136","DOI":"10.1073\/pnas.1415191111","volume":"111","author":"GE Hodes","year":"2014","unstructured":"Hodes GE, Pfau ML, Leboeuf M, Golden SA, Christoffel DJ, Bregman D, et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci USA. 2014;111:16136\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"key":"177_CR63","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.biopsych.2015.12.009","volume":"80","author":"J Wook Koo","year":"2016","unstructured":"Wook Koo J, Labonte B, Engmann O, Calipari ES, Juarez B, Lorsch Z, et al. Essential role of mesolimbic brain-derived neurotrophic factor in chronic social stress-induced depressive behaviors. Biol Psychiatry. 2016;80:469\u201378.","journal-title":"Biol Psychiatry"},{"key":"177_CR64","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1523\/JNEUROSCI.3723-13.2014","volume":"34","author":"ES Wohleb","year":"2014","unstructured":"Wohleb ES, Patterson JM, Sharma V, Quan N, Godbout JP, Sheridan JF. Knockdown of interleukin-1 receptor type-1 on endothelial cells attenuated stress-induced neuroinflammation and prevented anxiety-like behavior. J Neurosci. 2014;34:2583\u201391.","journal-title":"J Neurosci"},{"key":"177_CR65","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2016.05.038","volume":"91","author":"R Hultman","year":"2016","unstructured":"Hultman R, Mague SD, Li Q, Katz BM, Michel N, Lin L, et al. Dysregulation of prefrontal cortex-mediated slow-evolving limbic dynamics drives stress-induced emotional pathology. Neuron. 2016;91:439\u201352.","journal-title":"Neuron"},{"key":"177_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5537","volume":"5","author":"S Kumar","year":"2014","unstructured":"Kumar S, Hultman R, Hughes D, Michel N, Katz BM, Dzirasa K. Prefrontal cortex reactivity underlies trait vulnerability to chronic social defeat stress. Nat Commun. 2014;5:4537.","journal-title":"Nat Commun"},{"key":"177_CR67","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1038\/npp.2016.58","volume":"41","author":"RX Zhang","year":"2016","unstructured":"Zhang RX, Han Y, Chen C, Xu LZ, Li JL, Chen N, et al. EphB2 in the medial prefrontal cortex regulates vulnerability to stress. Neuropsychopharmacology. 2016;41:2541\u201356.","journal-title":"Neuropsychopharmacology"},{"key":"177_CR68","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1038\/s41593-017-0010-3","volume":"20","author":"C Menard","year":"2017","unstructured":"Menard C, Pfau ML, Hodes GE, Kana V, Wang VX, Bouchard S, et al. Social stress induces neurovascular pathology promoting depression. Nat Neurosci. 2017;20:1752\u201360.","journal-title":"Nat Neurosci"},{"key":"177_CR69","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.bbi.2004.11.002","volume":"19","author":"G Beitia","year":"2005","unstructured":"Beitia G, Garmendia L, Azpiroz A, Vegas O, Brain PF, Arregi A. Time-dependent behavioral, neurochemical, and immune consequences of repeated experiences of social defeat stress in male mice and the ameliorative effects of fluoxetine. Brain Behav Immun. 2005;19:530\u20139.","journal-title":"Brain Behav Immun"},{"key":"177_CR70","doi-asserted-by":"publisher","first-page":"16453","DOI":"10.1523\/JNEUROSCI.3177-10.2010","volume":"30","author":"JL Cao","year":"2010","unstructured":"Cao JL, Covington HE 3rd, Friedman AK, Wilkinson MB, Walsh JJ, Cooper DC, et al. Mesolimbic dopamine neurons in the brain reward circuit mediate susceptibility to social defeat and antidepressant action. J Neurosci. 2010;30:16453\u20138.","journal-title":"J Neurosci"},{"key":"177_CR71","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nn.2551","volume":"13","author":"V Vialou","year":"2010","unstructured":"Vialou V, Robison AJ, Laplant QC, Covington HE 3rd, Dietz DM, et al. DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat Neurosci. 2010;13:745\u201352.","journal-title":"Nat Neurosci"},{"key":"177_CR72","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1523\/JNEUROSCI.1787-13.2014","volume":"34","author":"V Vialou","year":"2014","unstructured":"Vialou V, Bagot RC, Cahill ME, Ferguson D, Robison AJ, Dietz DM, et al. Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of DeltaFosB. J Neurosci. 2014;34:3878\u201387.","journal-title":"J Neurosci"},{"key":"177_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.43","volume":"7","author":"H Jiang","year":"2017","unstructured":"Jiang H, Chen S, Li C, Lu N, Yue Y, Yin Y, et al. The serum protein levels of the tPA-BDNF pathway are implicated in depression and antidepressant treatment. Transl Psychiatry. 2017;7:e1079.","journal-title":"Transl Psychiatry"},{"key":"177_CR74","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1503\/jpn.120117","volume":"38","author":"L Kong","year":"2013","unstructured":"Kong L, Chen K, Tang Y, Wu F, Driesen N, Womer F, et al. Functional connectivity between the amygdala and prefrontal cortex in medication-naive individuals with major depressive disorder. J Psychiatry Neurosci. 2013;38:417\u201322.","journal-title":"J Psychiatry Neurosci"},{"key":"177_CR75","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.nbd.2015.03.011","volume":"77","author":"V Reinhart","year":"2015","unstructured":"Reinhart V, Bove SE, Volfson D, Lewis DA, Kleiman RJ, Lanz TA. Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder. Neurobiol Dis. 2015;77:220\u20137.","journal-title":"Neurobiol Dis"},{"key":"177_CR76","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jad.2011.04.021","volume":"133","author":"JR Teyssier","year":"2011","unstructured":"Teyssier JR, Ragot S, Chauvet-Gelinier JC, Trojak B, Bonin B. Activation of a DeltaFOSB dependent gene expression pattern in the dorsolateral prefrontal cortex of patients with major depressive disorder. J Affect Disord. 2011;133:174\u20138.","journal-title":"J Affect Disord"},{"key":"177_CR77","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.biopsych.2016.06.012","volume":"81","author":"RC Bagot","year":"2017","unstructured":"Bagot RC, Cates HM, Purushothaman I, Vialou V, Heller EA, Yieh L, et al. Ketamine and imipramine reverse transcriptional signatures of susceptibility and induce resilience-specific gene expression profiles. Biol Psychiatry. 2017;81:285\u201395.","journal-title":"Biol Psychiatry"},{"key":"177_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.136","volume":"5","author":"C Yang","year":"2015","unstructured":"Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632.","journal-title":"Transl Psychiatry"},{"key":"177_CR79","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/hbm.23085","volume":"37","author":"CT Li","year":"2016","unstructured":"Li CT, Chen MH, Lin WC, Hong CJ, Yang BH, Liu RS, et al. The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study. Hum Brain Mapp. 2016;37:1080\u201390.","journal-title":"Hum Brain Mapp"},{"key":"177_CR80","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/npp.2014.298","volume":"40","author":"JW Murrough","year":"2015","unstructured":"Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015;40:1084\u201390.","journal-title":"Neuropsychopharmacology"},{"key":"177_CR81","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","volume":"173","author":"JB Singh","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173:816\u201326.","journal-title":"Am J Psychiatry"},{"key":"177_CR82","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.celrep.2016.05.067","volume":"16","author":"ME Soden","year":"2016","unstructured":"Soden ME, Miller SM, Burgeno LM, Phillips PEM, Hnasko TS, Zweifel LS. Genetic isolation of hypothalamic neurons that regulate context-specific male social behavior. Cell Rep. 2016;16:304\u201313.","journal-title":"Cell Rep"},{"key":"177_CR83","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1038\/npp.2015.81","volume":"40","author":"I Mesic","year":"2015","unstructured":"Mesic I, Guzman YF, Guedea AL, Jovasevic V, Corcoran KA, Leaderbrand K, et al. Double dissociation of the roles of metabotropic glutamate receptor 5 and oxytocin receptor in discrete social behaviors. Neuropsychopharmacology. 2015;40:2337\u201346.","journal-title":"Neuropsychopharmacology"},{"key":"177_CR84","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nn.3927","volume":"18","author":"W Chung","year":"2015","unstructured":"Chung W, Choi SY, Lee E, Park H, Kang J, Choi Y, et al. Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression. Nat Neurosci. 2015;18:435\u201343.","journal-title":"Nat Neurosci"},{"key":"177_CR85","doi-asserted-by":"crossref","unstructured":"Mingote S, Chuhma N, Kalmbach A, Thomsen GM, Wang Y, Mihali A, et al. Dopamine neuron dependent behaviors mediated by glutamate cotransmission. eLife. 2017;6:e27566.","DOI":"10.7554\/eLife.27566"},{"key":"177_CR86","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/glia.22758","volume":"63","author":"C Cardona","year":"2015","unstructured":"Cardona C, Sanchez-Mejias E, Davila JC, Martin-Rufian M, Campos-Sandoval JA, Vitorica J, et al. Expression of Gls and Gls2 glutaminase isoforms in astrocytes. Glia. 2015;63:365\u201382.","journal-title":"Glia"},{"key":"177_CR87","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clim.2016.08.019","volume":"185","author":"SA Chalmers","year":"2017","unstructured":"Chalmers SA, Wen J, Shum J, Doerner J, Herlitz L, Putterman C. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus. Clin Immunol. 2017;185:100\u20138.","journal-title":"Clin Immunol"},{"key":"177_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-017-0307-x","volume":"10","author":"J Han","year":"2017","unstructured":"Han J, Harris RA, Zhang XM. An updated assessment of microglia depletion: current concepts and future directions. Mol Brain. 2017;10:25.","journal-title":"Mol Brain"},{"key":"177_CR89","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/npp.2017.88","volume":"43","author":"PJ Hamilton","year":"2018","unstructured":"Hamilton PJ, Burek DJ, Lombroso SI, Neve RL, Robison AJ, Nestler EJ, et al. Cell-type-specific epigenetic editing at the Fosb gene controls susceptibility to social defeat stress. Neuropsychopharmacology. 2018;43:272\u201384.","journal-title":"Neuropsychopharmacology"},{"key":"177_CR90","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1073\/pnas.1719014115","volume":"115","author":"M Heshmati","year":"2018","unstructured":"Heshmati M, Aleyasin H, Menard C, Christoffel DJ, Flanigan ME, Pfau ML, et al. Cell-type-specific role for nucleus accumbens neuroligin-2 in depression and stress susceptibility. Proc Natl Acad Sci USA. 2018;115:1111\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"177_CR91","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/npp.2015.316","volume":"41","author":"YS Mineur","year":"2016","unstructured":"Mineur YS, Fote GM, Blakeman S, Cahuzac EL, Newbold SA, Picciotto MR. Multiple nicotinic acetylcholine receptor subtypes in the mouse amygdala regulate affective behaviors and response to social stress. Neuropsychopharmacology. 2016;41:1579\u201387.","journal-title":"Neuropsychopharmacology"},{"key":"177_CR92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","volume":"70","author":"CL Raison","year":"2013","unstructured":"Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31\u201341.","journal-title":"JAMA Psychiatry"},{"key":"177_CR93","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1001\/jamapsychiatry.2014.2427","volume":"72","author":"E Setiawan","year":"2015","unstructured":"Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72:268\u201375.","journal-title":"JAMA Psychiatry"},{"key":"177_CR94","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/mp.2010.52","volume":"16","author":"RC Shelton","year":"2011","unstructured":"Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA, et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry. 2011;16:751\u201362.","journal-title":"Mol Psychiatry"},{"key":"177_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mp.2016.245","volume":"22","author":"GA Vargish","year":"2017","unstructured":"Vargish GA, Pelkey KA, Yuan X, Chittajallu R, Collins D, Fang C, et al. Co-activation of VEGF and NMDA receptors promotes synaptic targeting of AMPA receptors. Mol Psychiatry. 2017;22:1.","journal-title":"Mol Psychiatry"},{"key":"177_CR96","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0163-7258(98)00042-4","volume":"81","author":"A Doble","year":"1999","unstructured":"Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol Ther. 1999;81:163\u2013221.","journal-title":"Pharmacol Ther"},{"key":"177_CR97","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10072-011-0828-5","volume":"33","author":"BB Kostandy","year":"2012","unstructured":"Kostandy BB. The role of glutamate in neuronal ischemic injury: the role of spark in fire. Neurol Sci. 2012;33:223\u201337.","journal-title":"Neurol Sci"},{"key":"177_CR98","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00424-010-0809-1","volume":"460","author":"A Lau","year":"2010","unstructured":"Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflug Arch. 2010;460:525\u201342.","journal-title":"Pflug Arch"}],"updated-by":[{"DOI":"10.1038\/s41386-019-0354-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T00:00:00Z","timestamp":1552435200000}}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0177-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0177-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:03:53Z","timestamp":1684602233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0177-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,13]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["177"],"URL":"https:\/\/doi.org\/10.1038\/s41386-018-0177-7","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,13]]},"assertion":[{"value":"2 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2019","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this Article omitted the following from the Acknowledgements: Under a license agreement between Dracen Pharmaceuticals, Inc. and the Johns Hopkins University, the University, Dr. Slusher, Dr. Rais, and Mr. Alt are entitled to royalty distributions related to technology used in the research described in this publication. In addition, Dr. Slusher, Dr. Majer and Dr. Rais are founders of and hold equity in Dracen Pharmaceuticals, Inc. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}